Drug intelligence / Profile preview

IDC113

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IDC113 is a first-in-class monoclonal antibody currently under development by Prestige Biopharma for the treatment of solid tumors. It is part of the company's innovative drug pipeline and is currently in the lead identification and preclinical stages. As a first-in-class therapeutic candidate, IDC113 is designed to target a novel biological pathway or antigen associated with tumor progression, although its specific molecular target has not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on IDC113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC113.

Explore the full profile